日本全国大规模调查中氰基丙烯酸酯闭合术治疗静脉曲张的安全性评估
日本监管委员会于2023年11月至12月开展全国调查,覆盖335家机构2020年1月至2023年10月接受氰基丙烯酸酯闭合术的24,209例患者。静脉血栓栓塞发生率为0.59%,局部血栓性静脉炎需额外治疗者为6.8%,无卒中或过敏性休克,1例死于肺栓塞。低容量机构近端深静脉血栓和消融相关血栓延伸发生率显著高于高容量中心。
要点
- 静脉血栓栓塞发生142例(0.59%),其中肺栓塞3例(0.01%)、近端深静脉血栓9例(0.04%)、消融相关血栓延伸95例(0.39%)。
- 需额外治疗的局部血栓性静脉炎1656例(6.8%);局部过敏反应中960例(58%)需口服抗组胺药,268例(16%)需口服和/或静脉激素。
- 低容量机构近端深静脉血栓发生率0.13% vs 高容量中心0.01%(P < .001;OR 12.5;95%CI 2.6-60.3)。
核心结论
- 日本全国调查显示氰基丙烯酸酯闭合术治疗静脉曲张安全,严重不良事件如静脉血栓栓塞发生率低。
- 但部分患者出现需激素治疗的过敏反应和全身过敏反应。
研究设计与样本
- 日本静脉曲张血管内治疗监管委员会于2023年11月至2023年12月开展全国调查。
- 数据来自1017家机构,覆盖335家机构2020年1月至2023年10月接受氰基丙烯酸酯闭合术的24,209例患者。
主要发现
- 静脉血栓栓塞142例(0.59%);肺栓塞3例(0.01%)、近端深静脉血栓9例(0.04%)、消融相关血栓延伸95例(0.39%)。
- 需额外治疗的局部血栓性静脉炎1656例(6.8%);局部过敏反应中960例(58%)需口服抗组胺药,268例(16%)需口服和/或静脉激素。
- 全身过敏反应需全身激素者65例(0.27%);无卒中或过敏性休克;1例死于肺栓塞。
- 因延迟感染(n=4)、过敏反应(n=4)或异物肉芽肿(n=1)行胶体取出术者9例。
- 低容量机构较高容量中心近端深静脉血栓发生率0.13% vs 0.01%(P < .001;OR 12.5;95%CI 2.6-60.3),消融相关血栓延伸发生率0.73% vs 0.30%(P < .001;OR 2.5;95%CI 1.66-3.77)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cyanoacrylate closure (CAC) is a minimally invasive technique for treating axial venous reflux. However, the incidence of serious adverse events (AEs) related to CAC is concerning. With an increasing number of patients undergoing CAC and insufficient safety data in Japan, this study aimed to investigate the safety profile of CAC, focusing on the types and incidence of AEs. METHODS: A nationwide survey was conducted by the Japanese Regulatory Committee for Endovascular Treatment of Varicose Veins between November 2023 and December 2023. Data were collected from 1017 institutions, covering 24,209 patients who underwent CAC at 335 institutions between January 2020 and October 2023. Thromboembolism, phlebitis, hypersensitivity reactions, granuloma formation, infection, bleeding, death, and need for glue resection were documented as unfavorable events or outcomes. RESULTS: Venous thromboembolism developed in 142 patients (0.59%). Pulmonary embolism, proximal deep vein thrombosis, and ablation-related thrombus extension developed in 3 (0.01%), 9 (0.04%), and 95 (0.39%) patients, respectively. Localized phlebitis that required additional treatment was observed in 1656 patients (6.8%). Of the localized hypersensitivity cases, 960 (58%) required oral antihistamines and 268 (16%) required oral and/or intravenous steroids. Furthermore, 65 patients (0.27%) developed systemic hypersensitivity that required systemic steroids. No patients developed a stroke or anaphylaxis. One patient died owing to pulmonary embolism. Glue resection was performed in nine patients with delayed infection (n = 4), hypersensitivity reactions (n = 4), or a foreign body granuloma (n = 1). The incidence of hypersensitivity reactions was similar among institutions. However, the incidence of thrombosis-related events significantly differed between the high-volume and low-volume institutions. The incidence of proximal deep vein thrombosis (0.13% vs 0.01%; P < .001; odds ratio, 12.5; 95% confidence interval, 2.6-60.3) and ablation-related thrombus extension (0.73% vs 0.30%; P < .001; odds ratio, 2.5; 95% confidence interval, 1.66-3.77) was significantly higher in low-volume institutions than in high-volume centers. CONCLUSIONS: A nationwide survey of CAC for varicose veins in Japan demonstrated that it was a safe procedure with a low rate of serious AEs, such as venous thromboembolism. However, hypersensitivity reactions requiring steroid administration and systemic allergic reactions were observed in some patients.
引用
- Umetsu M, Hirokawa M, Fukaya E, et al. Safety assessment of cyanoacrylate closure for treatment of varicose veins in a large-scale national survey in Japan. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 39706258. doi:10.1016/j.jvsv.2024.102160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。